Anticancer Drugs Lanreotide Oncology Pharmacology Physiotherapy


In this article we will discuss Lanreotide (Dosage Overview)

In this article, we will discuss Lanreotide (Dosage Overview). So, let’s get started.


Lanreotide Injection 60 mg, 90 mg, and 120 mg is indicated for the long-term
treatment of acromegalic patients who have had an inadequate response to surgery and/or radiotherapy, or for whom surgery and/or radiotherapy is not an option.
The goal of treatment in acromegaly is to reduce growth hormone (GH) and insulin growth factor-1 (IGF-1) levels to normal.

Gastroenteropancreatic neuroendocrine tumors
Lanreotide Injection 120 mg is indicated for the treatment of patients with unresectable, well or moderately-differentiated, locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs) to improve progression-free survival.


Patients should begin treatment with Lanreotide 90 mg given via the deep subcutaneous route, at 4-week intervals for 3 months. After 3 months, dosage may be adjusted as follows:
• GH greater than 1ng/mL to less than or equal to 2.5 ng/mL, IGF-1 normal, and clinical symptoms controlled: maintain Lanreotide dose at 90 mg every 4 weeks
• GH greater than 2.5 ng/mL, IGF-1 elevated, and/or clinical symptoms uncontrolled: increase Lanreotide dose to 120 mg every 4 weeks.
• GH less than or equal to 1 ng/mL, IGF-1 normal, and clinical symptoms controlled: reduce Lanreotide dose to 60 mg every 4 weeks. Thereafter, the dose should be adjusted according to the response of the patient as judged by a reduction in
serum GH and/or IGF-1 levels; and/or changes in symptoms of acromegaly. Patients who are controlled on Lanreotide 60 mg or 90 mg may be considered for an extended dosing interval of Lanreotide 120 mg every 6 or 8 weeks. GH and IGF-1 levels should be obtained 6 weeks after this change in dosing regimen to evaluate persistence of patient response.
Continued monitoring of patient response with dose adjustments for biochemical and clinical symptom control, as necessary, is recommended. The starting dose in patients with moderate or severe renal impairment or moderate or severe hepatic impairment should be 60 mg via the deep subcutaneous route at 4-week intervals for 3 months followed by dose adjustment as described above.

Gastroenteropancreatic Neuroendocrine Tumors
The recommended dose of Lanreotide is 120 mg administered every 4 weeks by deep
subcutaneous injection. There is no recommended dose adjustment for mild or moderate renal impairment. There is insufficient information to recommend a dose for patients with severe renal impairment or with hepatic impairment of any severity.

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.